Rasuvo

Polymyositis, Uveitis, Prophylaxis against graft versus host disease + 27 more

Treatment

20 Active Studies for Rasuvo

What is Rasuvo

Methotrexate

The Generic name of this drug

Treatment Summary

Methotrexate is a medication used to reduce inflammation and stop cell division. It is commonly prescribed to treat certain types of arthritis, severe psoriasis, and certain forms of cancer, such as breast cancer and non-Hodgkin's lymphoma. This drug can cause side effects, so it is only used when other treatments have failed or if a patient is not able to tolerate them. Methotrexate was approved by the FDA in 1953.

Methotrexate

is the brand name

image of different drug pills on a surface

Rasuvo Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Methotrexate

Methotrexate

1953

137

Effectiveness

How Rasuvo Affects Patients

Methotrexate works by blocking enzymes that are involved in making new cells, resulting in reduced inflammation. It usually needs to be taken only once a week, but it is a powerful drug and should be taken carefully. Do not take methotrexate daily, as this could be dangerous.

How Rasuvo works in the body

Methotrexate prevents cells from dividing by blocking enzymes responsible for making nucleotides. In rheumatoid arthritis, this process also causes a buildup of adenosine in the body, which activates anti-inflammatory receptors to reduce inflammation.

When to interrupt dosage

The quantity of Rasuvo is contingent upon the diagnosed condition, including Uveitis, Polymyositis and nonleukemic meningeal cancer. The dosage is dependent upon the mode of delivery, as listed in the table below.

Condition

Dosage

Administration

Takayasu Arteritis

25.0 mg/mL, , 2.5 mg, 100.0 mg/mL, 25.0 mg, 7.5 mg, 10.0 mg, 15.0 mg, 20.0 mg, 50.0 mg, 150.0 mg/mL, 200.0 mg/mL, 250.0 mg/mL, 75.0 mg/mL, 125.0 mg/mL, 225.0 mg/mL, 175.0 mg/mL, 12.5 mg, 17.5 mg, 22.5 mg, 5.0 mg, 1000.0 mg, 2.5 mg/mL, 275.0 mg/mL, 300.0 mg/mL, 10.0 mg/mL, 20.0 mg/mL, 15.0 mg/mL, 2.0 mg/mL

, Injection, Injection - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Injection, solution, Injection, solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Intra-arterial; Intramuscular; Intrathecal; Intravenous, Oral, Tablet - Oral, Tablet, Intra-arterial; Intramuscular; Intravenous, Injection, solution - Intra-arterial; Intramuscular; Intravenous, Intravenous, Intramuscular; Intrathecal; Intravenous, Powder, for solution - Intramuscular; Intrathecal; Intravenous, Liquid, Liquid - Intramuscular; Intrathecal; Intravenous, Solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous; Intraventricular, Powder, for solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Injection, solution - Subcutaneous, Subcutaneous, Tablet, film coated, Tablet, film coated - Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Solution - Oral, Solution - Intravenous, Intra-arterial; Intramuscular; Intrathecal; Iontophoresis, Injection, solution - Intra-arterial; Intramuscular; Intrathecal; Iontophoresis, Solution, Solution - Intra-arterial; Intramuscular; Intravenous, Solution - Subcutaneous, Solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Liquid - Intravenous, Liquid - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Powder, for solution, Intra-arterial; Intramuscular; Intrathecal; Intravenous; Intraventricular

Medically induced abortion

25.0 mg/mL, , 2.5 mg, 100.0 mg/mL, 25.0 mg, 7.5 mg, 10.0 mg, 15.0 mg, 20.0 mg, 50.0 mg, 150.0 mg/mL, 200.0 mg/mL, 250.0 mg/mL, 75.0 mg/mL, 125.0 mg/mL, 225.0 mg/mL, 175.0 mg/mL, 12.5 mg, 17.5 mg, 22.5 mg, 5.0 mg, 1000.0 mg, 2.5 mg/mL, 275.0 mg/mL, 300.0 mg/mL, 10.0 mg/mL, 20.0 mg/mL, 15.0 mg/mL, 2.0 mg/mL

, Injection, Injection - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Injection, solution, Injection, solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Intra-arterial; Intramuscular; Intrathecal; Intravenous, Oral, Tablet - Oral, Tablet, Intra-arterial; Intramuscular; Intravenous, Injection, solution - Intra-arterial; Intramuscular; Intravenous, Intravenous, Intramuscular; Intrathecal; Intravenous, Powder, for solution - Intramuscular; Intrathecal; Intravenous, Liquid, Liquid - Intramuscular; Intrathecal; Intravenous, Solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous; Intraventricular, Powder, for solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Injection, solution - Subcutaneous, Subcutaneous, Tablet, film coated, Tablet, film coated - Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Solution - Oral, Solution - Intravenous, Intra-arterial; Intramuscular; Intrathecal; Iontophoresis, Injection, solution - Intra-arterial; Intramuscular; Intrathecal; Iontophoresis, Solution, Solution - Intra-arterial; Intramuscular; Intravenous, Solution - Subcutaneous, Solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Liquid - Intravenous, Liquid - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Powder, for solution, Intra-arterial; Intramuscular; Intrathecal; Intravenous; Intraventricular

Acute Promyelocytic Leukemia

25.0 mg/mL, , 2.5 mg, 100.0 mg/mL, 25.0 mg, 7.5 mg, 10.0 mg, 15.0 mg, 20.0 mg, 50.0 mg, 150.0 mg/mL, 200.0 mg/mL, 250.0 mg/mL, 75.0 mg/mL, 125.0 mg/mL, 225.0 mg/mL, 175.0 mg/mL, 12.5 mg, 17.5 mg, 22.5 mg, 5.0 mg, 1000.0 mg, 2.5 mg/mL, 275.0 mg/mL, 300.0 mg/mL, 10.0 mg/mL, 20.0 mg/mL, 15.0 mg/mL, 2.0 mg/mL

, Injection, Injection - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Injection, solution, Injection, solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Intra-arterial; Intramuscular; Intrathecal; Intravenous, Oral, Tablet - Oral, Tablet, Intra-arterial; Intramuscular; Intravenous, Injection, solution - Intra-arterial; Intramuscular; Intravenous, Intravenous, Intramuscular; Intrathecal; Intravenous, Powder, for solution - Intramuscular; Intrathecal; Intravenous, Liquid, Liquid - Intramuscular; Intrathecal; Intravenous, Solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous; Intraventricular, Powder, for solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Injection, solution - Subcutaneous, Subcutaneous, Tablet, film coated, Tablet, film coated - Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Solution - Oral, Solution - Intravenous, Intra-arterial; Intramuscular; Intrathecal; Iontophoresis, Injection, solution - Intra-arterial; Intramuscular; Intrathecal; Iontophoresis, Solution, Solution - Intra-arterial; Intramuscular; Intravenous, Solution - Subcutaneous, Solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Liquid - Intravenous, Liquid - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Powder, for solution, Intra-arterial; Intramuscular; Intrathecal; Intravenous; Intraventricular

Soft Tissue Sarcoma

25.0 mg/mL, , 2.5 mg, 100.0 mg/mL, 25.0 mg, 7.5 mg, 10.0 mg, 15.0 mg, 20.0 mg, 50.0 mg, 150.0 mg/mL, 200.0 mg/mL, 250.0 mg/mL, 75.0 mg/mL, 125.0 mg/mL, 225.0 mg/mL, 175.0 mg/mL, 12.5 mg, 17.5 mg, 22.5 mg, 5.0 mg, 1000.0 mg, 2.5 mg/mL, 275.0 mg/mL, 300.0 mg/mL, 10.0 mg/mL, 20.0 mg/mL, 15.0 mg/mL, 2.0 mg/mL

, Injection, Injection - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Injection, solution, Injection, solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Intra-arterial; Intramuscular; Intrathecal; Intravenous, Oral, Tablet - Oral, Tablet, Intra-arterial; Intramuscular; Intravenous, Injection, solution - Intra-arterial; Intramuscular; Intravenous, Intravenous, Intramuscular; Intrathecal; Intravenous, Powder, for solution - Intramuscular; Intrathecal; Intravenous, Liquid, Liquid - Intramuscular; Intrathecal; Intravenous, Solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous; Intraventricular, Powder, for solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Injection, solution - Subcutaneous, Subcutaneous, Tablet, film coated, Tablet, film coated - Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Solution - Oral, Solution - Intravenous, Intra-arterial; Intramuscular; Intrathecal; Iontophoresis, Injection, solution - Intra-arterial; Intramuscular; Intrathecal; Iontophoresis, Solution, Solution - Intra-arterial; Intramuscular; Intravenous, Solution - Subcutaneous, Solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Liquid - Intravenous, Liquid - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Powder, for solution, Intra-arterial; Intramuscular; Intrathecal; Intravenous; Intraventricular

Chronic Graft Versus Host Disease

25.0 mg/mL, , 2.5 mg, 100.0 mg/mL, 25.0 mg, 7.5 mg, 10.0 mg, 15.0 mg, 20.0 mg, 50.0 mg, 150.0 mg/mL, 200.0 mg/mL, 250.0 mg/mL, 75.0 mg/mL, 125.0 mg/mL, 225.0 mg/mL, 175.0 mg/mL, 12.5 mg, 17.5 mg, 22.5 mg, 5.0 mg, 1000.0 mg, 2.5 mg/mL, 275.0 mg/mL, 300.0 mg/mL, 10.0 mg/mL, 20.0 mg/mL, 15.0 mg/mL, 2.0 mg/mL

, Injection, Injection - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Injection, solution, Injection, solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Intra-arterial; Intramuscular; Intrathecal; Intravenous, Oral, Tablet - Oral, Tablet, Intra-arterial; Intramuscular; Intravenous, Injection, solution - Intra-arterial; Intramuscular; Intravenous, Intravenous, Intramuscular; Intrathecal; Intravenous, Powder, for solution - Intramuscular; Intrathecal; Intravenous, Liquid, Liquid - Intramuscular; Intrathecal; Intravenous, Solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous; Intraventricular, Powder, for solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Injection, solution - Subcutaneous, Subcutaneous, Tablet, film coated, Tablet, film coated - Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Solution - Oral, Solution - Intravenous, Intra-arterial; Intramuscular; Intrathecal; Iontophoresis, Injection, solution - Intra-arterial; Intramuscular; Intrathecal; Iontophoresis, Solution, Solution - Intra-arterial; Intramuscular; Intravenous, Solution - Subcutaneous, Solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Liquid - Intravenous, Liquid - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Powder, for solution, Intra-arterial; Intramuscular; Intrathecal; Intravenous; Intraventricular

Leukemia

25.0 mg/mL, , 2.5 mg, 100.0 mg/mL, 25.0 mg, 7.5 mg, 10.0 mg, 15.0 mg, 20.0 mg, 50.0 mg, 150.0 mg/mL, 200.0 mg/mL, 250.0 mg/mL, 75.0 mg/mL, 125.0 mg/mL, 225.0 mg/mL, 175.0 mg/mL, 12.5 mg, 17.5 mg, 22.5 mg, 5.0 mg, 1000.0 mg, 2.5 mg/mL, 275.0 mg/mL, 300.0 mg/mL, 10.0 mg/mL, 20.0 mg/mL, 15.0 mg/mL, 2.0 mg/mL

, Injection, Injection - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Injection, solution, Injection, solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Intra-arterial; Intramuscular; Intrathecal; Intravenous, Oral, Tablet - Oral, Tablet, Intra-arterial; Intramuscular; Intravenous, Injection, solution - Intra-arterial; Intramuscular; Intravenous, Intravenous, Intramuscular; Intrathecal; Intravenous, Powder, for solution - Intramuscular; Intrathecal; Intravenous, Liquid, Liquid - Intramuscular; Intrathecal; Intravenous, Solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous; Intraventricular, Powder, for solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Injection, solution - Subcutaneous, Subcutaneous, Tablet, film coated, Tablet, film coated - Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Solution - Oral, Solution - Intravenous, Intra-arterial; Intramuscular; Intrathecal; Iontophoresis, Injection, solution - Intra-arterial; Intramuscular; Intrathecal; Iontophoresis, Solution, Solution - Intra-arterial; Intramuscular; Intravenous, Solution - Subcutaneous, Solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Liquid - Intravenous, Liquid - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Powder, for solution, Intra-arterial; Intramuscular; Intrathecal; Intravenous; Intraventricular

Arthritis, Juvenile

25.0 mg/mL, , 2.5 mg, 100.0 mg/mL, 25.0 mg, 7.5 mg, 10.0 mg, 15.0 mg, 20.0 mg, 50.0 mg, 150.0 mg/mL, 200.0 mg/mL, 250.0 mg/mL, 75.0 mg/mL, 125.0 mg/mL, 225.0 mg/mL, 175.0 mg/mL, 12.5 mg, 17.5 mg, 22.5 mg, 5.0 mg, 1000.0 mg, 2.5 mg/mL, 275.0 mg/mL, 300.0 mg/mL, 10.0 mg/mL, 20.0 mg/mL, 15.0 mg/mL, 2.0 mg/mL

, Injection, Injection - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Injection, solution, Injection, solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Intra-arterial; Intramuscular; Intrathecal; Intravenous, Oral, Tablet - Oral, Tablet, Intra-arterial; Intramuscular; Intravenous, Injection, solution - Intra-arterial; Intramuscular; Intravenous, Intravenous, Intramuscular; Intrathecal; Intravenous, Powder, for solution - Intramuscular; Intrathecal; Intravenous, Liquid, Liquid - Intramuscular; Intrathecal; Intravenous, Solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous; Intraventricular, Powder, for solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Injection, solution - Subcutaneous, Subcutaneous, Tablet, film coated, Tablet, film coated - Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Solution - Oral, Solution - Intravenous, Intra-arterial; Intramuscular; Intrathecal; Iontophoresis, Injection, solution - Intra-arterial; Intramuscular; Intrathecal; Iontophoresis, Solution, Solution - Intra-arterial; Intramuscular; Intravenous, Solution - Subcutaneous, Solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Liquid - Intravenous, Liquid - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Powder, for solution, Intra-arterial; Intramuscular; Intrathecal; Intravenous; Intraventricular

Polymyositis

25.0 mg/mL, , 2.5 mg, 100.0 mg/mL, 25.0 mg, 7.5 mg, 10.0 mg, 15.0 mg, 20.0 mg, 50.0 mg, 150.0 mg/mL, 200.0 mg/mL, 250.0 mg/mL, 75.0 mg/mL, 125.0 mg/mL, 225.0 mg/mL, 175.0 mg/mL, 12.5 mg, 17.5 mg, 22.5 mg, 5.0 mg, 1000.0 mg, 2.5 mg/mL, 275.0 mg/mL, 300.0 mg/mL, 10.0 mg/mL, 20.0 mg/mL, 15.0 mg/mL, 2.0 mg/mL

, Injection, Injection - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Injection, solution, Injection, solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Intra-arterial; Intramuscular; Intrathecal; Intravenous, Oral, Tablet - Oral, Tablet, Intra-arterial; Intramuscular; Intravenous, Injection, solution - Intra-arterial; Intramuscular; Intravenous, Intravenous, Intramuscular; Intrathecal; Intravenous, Powder, for solution - Intramuscular; Intrathecal; Intravenous, Liquid, Liquid - Intramuscular; Intrathecal; Intravenous, Solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous; Intraventricular, Powder, for solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Injection, solution - Subcutaneous, Subcutaneous, Tablet, film coated, Tablet, film coated - Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Solution - Oral, Solution - Intravenous, Intra-arterial; Intramuscular; Intrathecal; Iontophoresis, Injection, solution - Intra-arterial; Intramuscular; Intrathecal; Iontophoresis, Solution, Solution - Intra-arterial; Intramuscular; Intravenous, Solution - Subcutaneous, Solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Liquid - Intravenous, Liquid - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Powder, for solution, Intra-arterial; Intramuscular; Intrathecal; Intravenous; Intraventricular

Uveitis

25.0 mg/mL, , 2.5 mg, 100.0 mg/mL, 25.0 mg, 7.5 mg, 10.0 mg, 15.0 mg, 20.0 mg, 50.0 mg, 150.0 mg/mL, 200.0 mg/mL, 250.0 mg/mL, 75.0 mg/mL, 125.0 mg/mL, 225.0 mg/mL, 175.0 mg/mL, 12.5 mg, 17.5 mg, 22.5 mg, 5.0 mg, 1000.0 mg, 2.5 mg/mL, 275.0 mg/mL, 300.0 mg/mL, 10.0 mg/mL, 20.0 mg/mL, 15.0 mg/mL, 2.0 mg/mL

, Injection, Injection - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Injection, solution, Injection, solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Intra-arterial; Intramuscular; Intrathecal; Intravenous, Oral, Tablet - Oral, Tablet, Intra-arterial; Intramuscular; Intravenous, Injection, solution - Intra-arterial; Intramuscular; Intravenous, Intravenous, Intramuscular; Intrathecal; Intravenous, Powder, for solution - Intramuscular; Intrathecal; Intravenous, Liquid, Liquid - Intramuscular; Intrathecal; Intravenous, Solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous; Intraventricular, Powder, for solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Injection, solution - Subcutaneous, Subcutaneous, Tablet, film coated, Tablet, film coated - Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Solution - Oral, Solution - Intravenous, Intra-arterial; Intramuscular; Intrathecal; Iontophoresis, Injection, solution - Intra-arterial; Intramuscular; Intrathecal; Iontophoresis, Solution, Solution - Intra-arterial; Intramuscular; Intravenous, Solution - Subcutaneous, Solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Liquid - Intravenous, Liquid - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Powder, for solution, Intra-arterial; Intramuscular; Intrathecal; Intravenous; Intraventricular

Chemotherapy

25.0 mg/mL, , 2.5 mg, 100.0 mg/mL, 25.0 mg, 7.5 mg, 10.0 mg, 15.0 mg, 20.0 mg, 50.0 mg, 150.0 mg/mL, 200.0 mg/mL, 250.0 mg/mL, 75.0 mg/mL, 125.0 mg/mL, 225.0 mg/mL, 175.0 mg/mL, 12.5 mg, 17.5 mg, 22.5 mg, 5.0 mg, 1000.0 mg, 2.5 mg/mL, 275.0 mg/mL, 300.0 mg/mL, 10.0 mg/mL, 20.0 mg/mL, 15.0 mg/mL, 2.0 mg/mL

, Injection, Injection - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Injection, solution, Injection, solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Intra-arterial; Intramuscular; Intrathecal; Intravenous, Oral, Tablet - Oral, Tablet, Intra-arterial; Intramuscular; Intravenous, Injection, solution - Intra-arterial; Intramuscular; Intravenous, Intravenous, Intramuscular; Intrathecal; Intravenous, Powder, for solution - Intramuscular; Intrathecal; Intravenous, Liquid, Liquid - Intramuscular; Intrathecal; Intravenous, Solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous; Intraventricular, Powder, for solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Injection, solution - Subcutaneous, Subcutaneous, Tablet, film coated, Tablet, film coated - Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Solution - Oral, Solution - Intravenous, Intra-arterial; Intramuscular; Intrathecal; Iontophoresis, Injection, solution - Intra-arterial; Intramuscular; Intrathecal; Iontophoresis, Solution, Solution - Intra-arterial; Intramuscular; Intravenous, Solution - Subcutaneous, Solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Liquid - Intravenous, Liquid - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Powder, for solution, Intra-arterial; Intramuscular; Intrathecal; Intravenous; Intraventricular

Psoriasis

25.0 mg/mL, , 2.5 mg, 100.0 mg/mL, 25.0 mg, 7.5 mg, 10.0 mg, 15.0 mg, 20.0 mg, 50.0 mg, 150.0 mg/mL, 200.0 mg/mL, 250.0 mg/mL, 75.0 mg/mL, 125.0 mg/mL, 225.0 mg/mL, 175.0 mg/mL, 12.5 mg, 17.5 mg, 22.5 mg, 5.0 mg, 1000.0 mg, 2.5 mg/mL, 275.0 mg/mL, 300.0 mg/mL, 10.0 mg/mL, 20.0 mg/mL, 15.0 mg/mL, 2.0 mg/mL

, Injection, Injection - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Injection, solution, Injection, solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Intra-arterial; Intramuscular; Intrathecal; Intravenous, Oral, Tablet - Oral, Tablet, Intra-arterial; Intramuscular; Intravenous, Injection, solution - Intra-arterial; Intramuscular; Intravenous, Intravenous, Intramuscular; Intrathecal; Intravenous, Powder, for solution - Intramuscular; Intrathecal; Intravenous, Liquid, Liquid - Intramuscular; Intrathecal; Intravenous, Solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous; Intraventricular, Powder, for solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Injection, solution - Subcutaneous, Subcutaneous, Tablet, film coated, Tablet, film coated - Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Solution - Oral, Solution - Intravenous, Intra-arterial; Intramuscular; Intrathecal; Iontophoresis, Injection, solution - Intra-arterial; Intramuscular; Intrathecal; Iontophoresis, Solution, Solution - Intra-arterial; Intramuscular; Intravenous, Solution - Subcutaneous, Solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Liquid - Intravenous, Liquid - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Powder, for solution, Intra-arterial; Intramuscular; Intrathecal; Intravenous; Intraventricular

Leukemia

25.0 mg/mL, , 2.5 mg, 100.0 mg/mL, 25.0 mg, 7.5 mg, 10.0 mg, 15.0 mg, 20.0 mg, 50.0 mg, 150.0 mg/mL, 200.0 mg/mL, 250.0 mg/mL, 75.0 mg/mL, 125.0 mg/mL, 225.0 mg/mL, 175.0 mg/mL, 12.5 mg, 17.5 mg, 22.5 mg, 5.0 mg, 1000.0 mg, 2.5 mg/mL, 275.0 mg/mL, 300.0 mg/mL, 10.0 mg/mL, 20.0 mg/mL, 15.0 mg/mL, 2.0 mg/mL

, Injection, Injection - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Injection, solution, Injection, solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Intra-arterial; Intramuscular; Intrathecal; Intravenous, Oral, Tablet - Oral, Tablet, Intra-arterial; Intramuscular; Intravenous, Injection, solution - Intra-arterial; Intramuscular; Intravenous, Intravenous, Intramuscular; Intrathecal; Intravenous, Powder, for solution - Intramuscular; Intrathecal; Intravenous, Liquid, Liquid - Intramuscular; Intrathecal; Intravenous, Solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous; Intraventricular, Powder, for solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Injection, solution - Subcutaneous, Subcutaneous, Tablet, film coated, Tablet, film coated - Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Solution - Oral, Solution - Intravenous, Intra-arterial; Intramuscular; Intrathecal; Iontophoresis, Injection, solution - Intra-arterial; Intramuscular; Intrathecal; Iontophoresis, Solution, Solution - Intra-arterial; Intramuscular; Intravenous, Solution - Subcutaneous, Solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Liquid - Intravenous, Liquid - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Powder, for solution, Intra-arterial; Intramuscular; Intrathecal; Intravenous; Intraventricular

Lymphoma, Non-Hodgkin

25.0 mg/mL, , 2.5 mg, 100.0 mg/mL, 25.0 mg, 7.5 mg, 10.0 mg, 15.0 mg, 20.0 mg, 50.0 mg, 150.0 mg/mL, 200.0 mg/mL, 250.0 mg/mL, 75.0 mg/mL, 125.0 mg/mL, 225.0 mg/mL, 175.0 mg/mL, 12.5 mg, 17.5 mg, 22.5 mg, 5.0 mg, 1000.0 mg, 2.5 mg/mL, 275.0 mg/mL, 300.0 mg/mL, 10.0 mg/mL, 20.0 mg/mL, 15.0 mg/mL, 2.0 mg/mL

, Injection, Injection - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Injection, solution, Injection, solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Intra-arterial; Intramuscular; Intrathecal; Intravenous, Oral, Tablet - Oral, Tablet, Intra-arterial; Intramuscular; Intravenous, Injection, solution - Intra-arterial; Intramuscular; Intravenous, Intravenous, Intramuscular; Intrathecal; Intravenous, Powder, for solution - Intramuscular; Intrathecal; Intravenous, Liquid, Liquid - Intramuscular; Intrathecal; Intravenous, Solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous; Intraventricular, Powder, for solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Injection, solution - Subcutaneous, Subcutaneous, Tablet, film coated, Tablet, film coated - Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Solution - Oral, Solution - Intravenous, Intra-arterial; Intramuscular; Intrathecal; Iontophoresis, Injection, solution - Intra-arterial; Intramuscular; Intrathecal; Iontophoresis, Solution, Solution - Intra-arterial; Intramuscular; Intravenous, Solution - Subcutaneous, Solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Liquid - Intravenous, Liquid - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Powder, for solution, Intra-arterial; Intramuscular; Intrathecal; Intravenous; Intraventricular

Dermatomyositis

25.0 mg/mL, , 2.5 mg, 100.0 mg/mL, 25.0 mg, 7.5 mg, 10.0 mg, 15.0 mg, 20.0 mg, 50.0 mg, 150.0 mg/mL, 200.0 mg/mL, 250.0 mg/mL, 75.0 mg/mL, 125.0 mg/mL, 225.0 mg/mL, 175.0 mg/mL, 12.5 mg, 17.5 mg, 22.5 mg, 5.0 mg, 1000.0 mg, 2.5 mg/mL, 275.0 mg/mL, 300.0 mg/mL, 10.0 mg/mL, 20.0 mg/mL, 15.0 mg/mL, 2.0 mg/mL

, Injection, Injection - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Injection, solution, Injection, solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Intra-arterial; Intramuscular; Intrathecal; Intravenous, Oral, Tablet - Oral, Tablet, Intra-arterial; Intramuscular; Intravenous, Injection, solution - Intra-arterial; Intramuscular; Intravenous, Intravenous, Intramuscular; Intrathecal; Intravenous, Powder, for solution - Intramuscular; Intrathecal; Intravenous, Liquid, Liquid - Intramuscular; Intrathecal; Intravenous, Solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous; Intraventricular, Powder, for solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Injection, solution - Subcutaneous, Subcutaneous, Tablet, film coated, Tablet, film coated - Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Solution - Oral, Solution - Intravenous, Intra-arterial; Intramuscular; Intrathecal; Iontophoresis, Injection, solution - Intra-arterial; Intramuscular; Intrathecal; Iontophoresis, Solution, Solution - Intra-arterial; Intramuscular; Intravenous, Solution - Subcutaneous, Solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Liquid - Intravenous, Liquid - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Powder, for solution, Intra-arterial; Intramuscular; Intrathecal; Intravenous; Intraventricular

Multiple Sclerosis

25.0 mg/mL, , 2.5 mg, 100.0 mg/mL, 25.0 mg, 7.5 mg, 10.0 mg, 15.0 mg, 20.0 mg, 50.0 mg, 150.0 mg/mL, 200.0 mg/mL, 250.0 mg/mL, 75.0 mg/mL, 125.0 mg/mL, 225.0 mg/mL, 175.0 mg/mL, 12.5 mg, 17.5 mg, 22.5 mg, 5.0 mg, 1000.0 mg, 2.5 mg/mL, 275.0 mg/mL, 300.0 mg/mL, 10.0 mg/mL, 20.0 mg/mL, 15.0 mg/mL, 2.0 mg/mL

, Injection, Injection - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Injection, solution, Injection, solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Intra-arterial; Intramuscular; Intrathecal; Intravenous, Oral, Tablet - Oral, Tablet, Intra-arterial; Intramuscular; Intravenous, Injection, solution - Intra-arterial; Intramuscular; Intravenous, Intravenous, Intramuscular; Intrathecal; Intravenous, Powder, for solution - Intramuscular; Intrathecal; Intravenous, Liquid, Liquid - Intramuscular; Intrathecal; Intravenous, Solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous; Intraventricular, Powder, for solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Injection, solution - Subcutaneous, Subcutaneous, Tablet, film coated, Tablet, film coated - Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Solution - Oral, Solution - Intravenous, Intra-arterial; Intramuscular; Intrathecal; Iontophoresis, Injection, solution - Intra-arterial; Intramuscular; Intrathecal; Iontophoresis, Solution, Solution - Intra-arterial; Intramuscular; Intravenous, Solution - Subcutaneous, Solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Liquid - Intravenous, Liquid - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Powder, for solution, Intra-arterial; Intramuscular; Intrathecal; Intravenous; Intraventricular

Breast Cancer

25.0 mg/mL, , 2.5 mg, 100.0 mg/mL, 25.0 mg, 7.5 mg, 10.0 mg, 15.0 mg, 20.0 mg, 50.0 mg, 150.0 mg/mL, 200.0 mg/mL, 250.0 mg/mL, 75.0 mg/mL, 125.0 mg/mL, 225.0 mg/mL, 175.0 mg/mL, 12.5 mg, 17.5 mg, 22.5 mg, 5.0 mg, 1000.0 mg, 2.5 mg/mL, 275.0 mg/mL, 300.0 mg/mL, 10.0 mg/mL, 20.0 mg/mL, 15.0 mg/mL, 2.0 mg/mL

, Injection, Injection - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Injection, solution, Injection, solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Intra-arterial; Intramuscular; Intrathecal; Intravenous, Oral, Tablet - Oral, Tablet, Intra-arterial; Intramuscular; Intravenous, Injection, solution - Intra-arterial; Intramuscular; Intravenous, Intravenous, Intramuscular; Intrathecal; Intravenous, Powder, for solution - Intramuscular; Intrathecal; Intravenous, Liquid, Liquid - Intramuscular; Intrathecal; Intravenous, Solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous; Intraventricular, Powder, for solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Injection, solution - Subcutaneous, Subcutaneous, Tablet, film coated, Tablet, film coated - Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Solution - Oral, Solution - Intravenous, Intra-arterial; Intramuscular; Intrathecal; Iontophoresis, Injection, solution - Intra-arterial; Intramuscular; Intrathecal; Iontophoresis, Solution, Solution - Intra-arterial; Intramuscular; Intravenous, Solution - Subcutaneous, Solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Liquid - Intravenous, Liquid - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Powder, for solution, Intra-arterial; Intramuscular; Intrathecal; Intravenous; Intraventricular

Lymphoma

25.0 mg/mL, , 2.5 mg, 100.0 mg/mL, 25.0 mg, 7.5 mg, 10.0 mg, 15.0 mg, 20.0 mg, 50.0 mg, 150.0 mg/mL, 200.0 mg/mL, 250.0 mg/mL, 75.0 mg/mL, 125.0 mg/mL, 225.0 mg/mL, 175.0 mg/mL, 12.5 mg, 17.5 mg, 22.5 mg, 5.0 mg, 1000.0 mg, 2.5 mg/mL, 275.0 mg/mL, 300.0 mg/mL, 10.0 mg/mL, 20.0 mg/mL, 15.0 mg/mL, 2.0 mg/mL

, Injection, Injection - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Injection, solution, Injection, solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Intra-arterial; Intramuscular; Intrathecal; Intravenous, Oral, Tablet - Oral, Tablet, Intra-arterial; Intramuscular; Intravenous, Injection, solution - Intra-arterial; Intramuscular; Intravenous, Intravenous, Intramuscular; Intrathecal; Intravenous, Powder, for solution - Intramuscular; Intrathecal; Intravenous, Liquid, Liquid - Intramuscular; Intrathecal; Intravenous, Solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous; Intraventricular, Powder, for solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Injection, solution - Subcutaneous, Subcutaneous, Tablet, film coated, Tablet, film coated - Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Solution - Oral, Solution - Intravenous, Intra-arterial; Intramuscular; Intrathecal; Iontophoresis, Injection, solution - Intra-arterial; Intramuscular; Intrathecal; Iontophoresis, Solution, Solution - Intra-arterial; Intramuscular; Intravenous, Solution - Subcutaneous, Solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Liquid - Intravenous, Liquid - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Powder, for solution, Intra-arterial; Intramuscular; Intrathecal; Intravenous; Intraventricular

Crohn's Disease

25.0 mg/mL, , 2.5 mg, 100.0 mg/mL, 25.0 mg, 7.5 mg, 10.0 mg, 15.0 mg, 20.0 mg, 50.0 mg, 150.0 mg/mL, 200.0 mg/mL, 250.0 mg/mL, 75.0 mg/mL, 125.0 mg/mL, 225.0 mg/mL, 175.0 mg/mL, 12.5 mg, 17.5 mg, 22.5 mg, 5.0 mg, 1000.0 mg, 2.5 mg/mL, 275.0 mg/mL, 300.0 mg/mL, 10.0 mg/mL, 20.0 mg/mL, 15.0 mg/mL, 2.0 mg/mL

, Injection, Injection - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Injection, solution, Injection, solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Intra-arterial; Intramuscular; Intrathecal; Intravenous, Oral, Tablet - Oral, Tablet, Intra-arterial; Intramuscular; Intravenous, Injection, solution - Intra-arterial; Intramuscular; Intravenous, Intravenous, Intramuscular; Intrathecal; Intravenous, Powder, for solution - Intramuscular; Intrathecal; Intravenous, Liquid, Liquid - Intramuscular; Intrathecal; Intravenous, Solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous; Intraventricular, Powder, for solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Injection, solution - Subcutaneous, Subcutaneous, Tablet, film coated, Tablet, film coated - Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Solution - Oral, Solution - Intravenous, Intra-arterial; Intramuscular; Intrathecal; Iontophoresis, Injection, solution - Intra-arterial; Intramuscular; Intrathecal; Iontophoresis, Solution, Solution - Intra-arterial; Intramuscular; Intravenous, Solution - Subcutaneous, Solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Liquid - Intravenous, Liquid - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Powder, for solution, Intra-arterial; Intramuscular; Intrathecal; Intravenous; Intraventricular

Lupus

25.0 mg/mL, , 2.5 mg, 100.0 mg/mL, 25.0 mg, 7.5 mg, 10.0 mg, 15.0 mg, 20.0 mg, 50.0 mg, 150.0 mg/mL, 200.0 mg/mL, 250.0 mg/mL, 75.0 mg/mL, 125.0 mg/mL, 225.0 mg/mL, 175.0 mg/mL, 12.5 mg, 17.5 mg, 22.5 mg, 5.0 mg, 1000.0 mg, 2.5 mg/mL, 275.0 mg/mL, 300.0 mg/mL, 10.0 mg/mL, 20.0 mg/mL, 15.0 mg/mL, 2.0 mg/mL

, Injection, Injection - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Injection, solution, Injection, solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Intra-arterial; Intramuscular; Intrathecal; Intravenous, Oral, Tablet - Oral, Tablet, Intra-arterial; Intramuscular; Intravenous, Injection, solution - Intra-arterial; Intramuscular; Intravenous, Intravenous, Intramuscular; Intrathecal; Intravenous, Powder, for solution - Intramuscular; Intrathecal; Intravenous, Liquid, Liquid - Intramuscular; Intrathecal; Intravenous, Solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous; Intraventricular, Powder, for solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Injection, solution - Subcutaneous, Subcutaneous, Tablet, film coated, Tablet, film coated - Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Solution - Oral, Solution - Intravenous, Intra-arterial; Intramuscular; Intrathecal; Iontophoresis, Injection, solution - Intra-arterial; Intramuscular; Intrathecal; Iontophoresis, Solution, Solution - Intra-arterial; Intramuscular; Intravenous, Solution - Subcutaneous, Solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Liquid - Intravenous, Liquid - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Powder, for solution, Intra-arterial; Intramuscular; Intrathecal; Intravenous; Intraventricular

Pregnancy, Ectopic

25.0 mg/mL, , 2.5 mg, 100.0 mg/mL, 25.0 mg, 7.5 mg, 10.0 mg, 15.0 mg, 20.0 mg, 50.0 mg, 150.0 mg/mL, 200.0 mg/mL, 250.0 mg/mL, 75.0 mg/mL, 125.0 mg/mL, 225.0 mg/mL, 175.0 mg/mL, 12.5 mg, 17.5 mg, 22.5 mg, 5.0 mg, 1000.0 mg, 2.5 mg/mL, 275.0 mg/mL, 300.0 mg/mL, 10.0 mg/mL, 20.0 mg/mL, 15.0 mg/mL, 2.0 mg/mL

, Injection, Injection - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Injection, solution, Injection, solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Intra-arterial; Intramuscular; Intrathecal; Intravenous, Oral, Tablet - Oral, Tablet, Intra-arterial; Intramuscular; Intravenous, Injection, solution - Intra-arterial; Intramuscular; Intravenous, Intravenous, Intramuscular; Intrathecal; Intravenous, Powder, for solution - Intramuscular; Intrathecal; Intravenous, Liquid, Liquid - Intramuscular; Intrathecal; Intravenous, Solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous; Intraventricular, Powder, for solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Injection, solution - Subcutaneous, Subcutaneous, Tablet, film coated, Tablet, film coated - Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Solution - Oral, Solution - Intravenous, Intra-arterial; Intramuscular; Intrathecal; Iontophoresis, Injection, solution - Intra-arterial; Intramuscular; Intrathecal; Iontophoresis, Solution, Solution - Intra-arterial; Intramuscular; Intravenous, Solution - Subcutaneous, Solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Liquid - Intravenous, Liquid - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Powder, for solution, Intra-arterial; Intramuscular; Intrathecal; Intravenous; Intraventricular

Warnings

Rasuvo Contraindications

Condition

Risk Level

Notes

Non Neoplastic Condition

Do Not Combine

Severe Hypersensitivity Reactions

Do Not Combine

Methotrexate may interact with Pulse Frequency

There are 20 known major drug interactions with Rasuvo.

Common Rasuvo Drug Interactions

Drug Name

Risk Level

Description

2-Methoxyethanol

Major

The risk or severity of adverse effects can be increased when Methotrexate is combined with 2-Methoxyethanol.

9-(N-methyl-L-isoleucine)-cyclosporin A

Major

The risk or severity of adverse effects can be increased when Methotrexate is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.

Abetimus

Major

The risk or severity of adverse effects can be increased when Methotrexate is combined with Abetimus.

Acteoside

Major

The risk or severity of adverse effects can be increased when Methotrexate is combined with Acteoside.

Aldosterone

Major

The risk or severity of adverse effects can be increased when Methotrexate is combined with Aldosterone.

Rasuvo Toxicity & Overdose Risk

The lowest toxic dose of etoposide in rats and mice has been found to be 135mg/kg and 146mg/kg, respectively. Symptoms of overdose may include reduced white blood cell, platelet, and red blood cell counts, mouth and stomach sores, nausea and vomiting, ulcers in the digestive tract, and bleeding. In the event of an overdose, patients should be treated with glucarpidase and not receive leucovorin within 2 hours before or after glucarpidase.

image of a doctor in a lab doing drug, clinical research

Rasuvo Novel Uses: Which Conditions Have a Clinical Trial Featuring Rasuvo?

764 active studies are underway to investigate the potential of Rasuvo in providing therapeutic benefit for Uveitis, Small Cell Lung Cancer and Soft Tissue Sarcoma.

Condition

Clinical Trials

Trial Phases

Soft Tissue Sarcoma

51 Actively Recruiting

Phase 2, Not Applicable, Phase 1, Phase 4, Early Phase 1, Phase 3

Non-Hodgkin's Lymphoma

115 Actively Recruiting

Phase 1, Phase 2, Not Applicable, Phase 3, Early Phase 1, Phase 4

Lupus

65 Actively Recruiting

Phase 2, Not Applicable, Phase 1, Phase 3, Phase 4, Early Phase 1

Bladder Cancer

101 Actively Recruiting

Phase 2, Not Applicable, Phase 1, Phase 3, Early Phase 1

Acute Lymphoblastic Leukemia

120 Actively Recruiting

Phase 1, Phase 2, Phase 3, Not Applicable, Early Phase 1, Phase 4

Multiple Sclerosis

127 Actively Recruiting

Phase 3, Not Applicable, Phase 4, Phase 2, Phase 1, Early Phase 1

Rheumatoid Arthritis

55 Actively Recruiting

Not Applicable, Phase 4, Phase 3, Phase 2, Phase 1

Hematopoietic stem cells

3 Actively Recruiting

Early Phase 1, Phase 1, Phase 2

Takayasu Arteritis

1 Actively Recruiting

Phase 2

Psoriasis

0 Actively Recruiting

Mycosis Fungoides

0 Actively Recruiting

Chemotherapy

4 Actively Recruiting

Phase 1, Phase 3, Not Applicable

Crohn's Disease

54 Actively Recruiting

Phase 1, Phase 2, Not Applicable, Phase 3, Phase 4, Early Phase 1

Acute Promyelocytic Leukemia

0 Actively Recruiting

Breast Cancer

21 Actively Recruiting

Phase 2, Phase 1, Not Applicable

Sarcoma

0 Actively Recruiting

Lymphoma

4 Actively Recruiting

Phase 1, Phase 2

Gestational Trophoblastic Disease

0 Actively Recruiting

Pregnancy, Ectopic

0 Actively Recruiting

Polymyositis

3 Actively Recruiting

Phase 2, Phase 3

Rasuvo Reviews: What are patients saying about Rasuvo?

4

Patient Review

11/20/2015

Rasuvo for Rheumatoid Arthritis

Rasuvo helped me avoid the gastrointestinal issues that come with taking methotrexate pills. However, the injections are painful and often leave large bruises that take weeks to heal.

3.7

Patient Review

11/10/2015

Rasuvo for Rheumatoid Arthritis

Easy and painless to use. I started with 12.5mg but may go to 15 mg. Definitely avoids the gastrointestinal problems that come with oral methotrexate.

2.7

Patient Review

11/7/2016

Rasuvo for Rheumatoid Arthritis

I had been on the methotrexate pills for about 18 years. After a bout with cancer last year they didn't seem to be as effective. My rheumatologist prescribed Resuvo about 4 months ago. I have noticed an increase in side effects, severe gastrointestinal distress, nausea, diarrhea, headaches, dizziness, confusion and blood in urine. I will not continue taking this medication

2.7

Patient Review

9/26/2015

Rasuvo for Rheumatoid Arthritis

Injecting this medication was not as easy or painless as the Otrexup injector.

1.3

Patient Review

11/3/2014

Rasuvo for Rheumatoid Arthritis

I've tried both Otrexup and Rasuvo. I definitely had a better experience with Otrexup-- it was easier to use and didn't hurt like Rasuvo did.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about rasuvo

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is Rasuvo injection?

"-

Rasuvo is a medication used to treat leukemia, certain types of cancer, severe psoriasis, and rheumatoid arthritis. It is also used to treat active polyarticular-course juvenile rheumatoid arthritis in children."

Answered by AI

Is Rasuvo a chemo drug?

"Methotrexate goes by various trade names, including Otrexup, Rasuvo, and Rheumatrex. It is an anti-cancer drug."

Answered by AI

Is Rasuvo the same as methotrexate?

"Rasuvo is a single-dose auto-injector containing the prescription medicine methotrexate."

Answered by AI

What is Rasuvo used for?

"Methotrexate, marketed as Rasuvo, is a drug used to manage severe cases of rheumatoid arthritis and juvenile idiopathic arthritis. It is intended for patients who have not responded well to non-steroidal anti-inflammatory drugs or who are unable to tolerate them."

Answered by AI

Clinical Trials for Rasuvo

Image of Wallace & Lee Center in Beverly Hills, United States.

BI 3000202 for Lupus

18 - 74
All Sexes
Beverly Hills, CA

This study is open to adults with systemic lupus erythematosus (SLE). The purpose of this study is to find out whether a medicine called BI 3000202 helps people with SLE. The study tests different doses of BI 3000202 and aims to find the best dose for people with this condition. Participants are put into 5 groups randomly, which means by chance. 4 groups get different doses of BI 3000202, and 1 group gets a placebo. Placebo tablets look like BI 3000202 tablets but do not contain any medicine. Participants take the tablets for 1 year. All participants also continue their regular treatment for SLE. Participants are in the study for a bit longer than 1 year. During this time, they visit the study site regularly. Doctors check the participants' health and take note of any unwanted effects. They also compare the results between the groups to see if the treatment works.

Phase 2
Waitlist Available

Wallace & Lee Center (+28 Sites)

Boehringer Ingelheim

Image of Michael E. DeBakey VA Medical Center, Houston, TX in Houston, United States.

Acceptance and Commitment Therapy for Inflammatory Bowel Disease

18+
All Sexes
Houston, TX

Many Veterans with gastrointestinal disorders, such as inflammatory bowel disease (IBD), also have mental health conditions. IBD and mental health conditions can worsen one another through the brain-gut axis, leading to dramatic deficits in psychosocial functioning and quality of life (QOL). Yet, few Veterans with comorbid IBD and mental health conditions receive psychotherapy and no evidence-based psychotherapies have been tested in Veterans with these comorbidities. Adapting brief acceptance and commitment therapy (ACT) to the specific to the needs of these patients and embedding treatment into routine gastroenterology care may increase Veterans' access to efficient and effective rehabilitative care. This study aims to adapt and test an integrated, 1-Day ACT intervention tailored to the specific needs of Veterans with IBD and mental health conditions to improve psychosocial functioning and QOL.

Waitlist Available
Has No Placebo

Michael E. DeBakey VA Medical Center, Houston, TX

Mackenzie Lynmarie Shanahan, PhD

Have you considered Rasuvo clinical trials?

We made a collection of clinical trials featuring Rasuvo, we think they might fit your search criteria.
Go to Trials
Image of University of Illinois at Chicago in Chicago, United States.

Functional Balance Intervention for Multiple Sclerosis

40 - 90
All Sexes
Chicago, IL

The study involves a two-arm, Phase 1, randomized controlled clinical trial designed to establish the feasibility and effects of a Functional Balance Intervention (FBI) on physical and cognitive function, as well as measures of daily living among persons with multiple sclerosis (PwMS). Combined Specific Aims: Aim 1: Examine the effect of the FBI (Intervention Group) on physical function in PwMS compared to a stretching program (Control Group). Hypothesis 1: After four months of training, the FBI group will show significantly greater improvements in physical function compared to the stretching group. Aim 2: Examine the effect of the multicomponent FBI on cognitive function in PwMS compared to the stretching program. Hypothesis 2: After four months of training, the FBI group will show significantly greater improvements in cognitive function compared to the stretching group. Aim 3: Examine the effects of the multicomponent FBI compared to the Control Group among PwMS on measures of daily living (dual-task performance, balance confidence, community mobility, and quality of life). Hypothesis 3: After four months of training, the FBI group will show significantly greater improvements in measures of daily living compared to the stretching group. All assessment sessions will be conducted virtually via Zoom. All measures collected during the initial screening, pre-training assessment, training progression, and mid- and post-training assessment sessions will be administered either via Zoom with a Helper Buddy present or through survey links sent to participants via the UIC REDCap system. The training sessions will be performed independently by the participants in the presence of a Helper Buddy. The investigators will recruit 75 people with multiple sclerosis (PwMS) for this study. Eligible participants will be randomized to either the FBI (Intervention) or stretching (Control) group, followed by an onboarding session with a designated Helper Buddy. Training will occur twice weekly for four months. Based on the anticipated attrition rate, the investigators aim for 40 PwMS to complete the post-training assessments and finish the study.

Recruiting
Has No Placebo

University of Illinois at Chicago

Image of National Institutes of Health Clinical Center in Bethesda, United States.

CD22 CAR T-cells for Acute Lymphoblastic Leukemia

3 - 65
All Sexes
Bethesda, MD

Background: Acute lymphoblastic leukemia (ALL) is a type of blood cancer. Chimeric antigen receptor (CAR) therapy involves taking immune cells (T cells) from a person and modifying them to better target cancer cells. CAR T-cell therapy that targets a marker called CD19 has been show to can cure ALL in many children and adults. But in about 50% of patients, the ALL comes back within a year. Researchers want to find out if a second treatment with CAR T-cell therapy that targets a different marker, CD22, can keep the cancer away longer. Objective: To see if CD22 CAR T-cell therapy can keep ALL away longer. Eligibility: People aged 3 to 65 years who have no signs of cancer after CD19 CAR T-cell treatment for ALL. Design: Participants will be screened. They will have imaging scans and tests of their heart function. A sample of tissue (biopsy) will be collected from their bone marrow. They will have a fluid sample collected from the area around their spinal cord. Participants will undergo collection of their white blood cells (T cells) during a procedure called leukapheresis. Blood will be taken from their body through a vein. The blood will pass through a machine that separates out the T cells. The remaining blood will be returned to the body through a different vein. The cells will be altered in a lab to create CD22 CAR T-cell therapy. Participants will take drugs over 4 consecutive days to prepare their body for the CAR T-cell therapy; then they will receive their modified T cells through a tube inserted into a vein. Some people may need to stay in the hospital during treatment. Participants will have follow-up visits for 2 years.

Phase 2
Waitlist Available

National Institutes of Health Clinical Center

Sara K Silbert, M.D.

Image of University of Iowa in Iowa City, United States.

Gemcitabine + Docetaxel for Bladder Cancer

18 - 99
All Sexes
Iowa City, IA

The goal of this clinical trial is to learn whether a combination of two chemotherapy drugs, Gemcitabine and Docetaxel, can treat high-grade non-muscle-invasive bladder cancer (HG-NMIBC) in adults whose cancer failed conventional BCG therapy. The drugs are given directly into the bladder (intravesically), one immediately after the other. The study will also assess the safety of this treatment. The main questions it aims to answer are: Can this drug combination effectively treat HG-NMIBC that did not respond to BCG and help prevent the cancer from coming back, offering long-term protection? What side effects or medical issues do participants experience during treatment? Researchers will evaluate this non-surgical approach as a potential alternative to bladder removal surgery (radical cystectomy), with the goal of validating it as a bladder-sparing option in this setting. Participants will: * Go through a screening process, including tumor removal and imaging tests * Receive weekly bladder treatments with Gemcitabine followed by Docetaxel for 6 weeks * If the cancer responds, continue with similar once monthly treatments (maintenance therapy) for up to 2 years * Attend regular check-ups, including bladder exams, urine tests, biopsies, and optional quality-of-life surveys * Possibly receive a second 6-week treatment cycle if the cancer returns early * Be followed for up to 5 years to monitor long-term outcomes

Phase 2
Waitlist Available

University of Iowa

Michael A O'Donnell, MD

Have you considered Rasuvo clinical trials?

We made a collection of clinical trials featuring Rasuvo, we think they might fit your search criteria.
Go to Trials
Image of MUHC - Montreal General Hospital in Montreal, Canada.

Ustekinumab for Crohn's Disease and Ulcerative Colitis

18+
All Sexes
Montreal, Canada

The goal of this clinical trial is to evaluate whether disease remission can be maintained when biologic therapy is reduced in patients with Crohn"s disease (CD) and ulcerative colitis (UC) taking ustekinumab (UST). The main question it aims to answer is: Can we de-escalate UST subcutaneous dose either from every 4 weeks (Q4) to every 8 weeks (Q8) or every 8 weeks (Q8) to every 12 weeks (Q12) in CD or UC patients in deep remission without loosing their response? Researchers will follow UST blood levels, inflammation markers and intestinal mucosa integrity and to see if UST dose can be reduced while maintaining clinical remission. Participants will: Change UST dosing from Q4 to Q8 or from Q8 to Q12. Visit the clinic once every 12 weeks for checkups and tests.

Phase 4
Recruiting

MUHC - Montreal General Hospital

Janssen Inc.

Have you considered Rasuvo clinical trials?

We made a collection of clinical trials featuring Rasuvo, we think they might fit your search criteria.
Go to Trials